Local recurrence of malignant tumor of urinary bladder (disorder)
BL-13
Year Started: 2019
A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Psychological data | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of cervix (disorder)
CRAIN
Year Started: 2022
A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Affected | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Affected | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| DNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Suspected bladder cancer (situation)
SPIRE- A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.
Year Started: 2016
SGI-110 is a DNA methyltransferase inhibitor developed for optimised delivery of the active metabolite decitabine. Pre-clinical data support that cisplatin resistance in bladder and other cancers is derived, at least in part, through promotor methylation of silenced genes relevant to a cisplatin resistance phenotype. Experimentally this is reversible through co-administration of DNA hypomethylating agents. The central hypothesis to be tested in this clinical trial is that SGI-110 can be safely combined with GC in bladder cancer at doses able to induce demethylation of genes associated with cisplatin resistance.
- Access:
- Open to applicants
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse non-Hodgkin's lymphoma (disorder)
Pola-R-ICE-polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) vs R-ICE in patients with primary refractory or relapsed DLBCL
Year Started: 2022
tissue specimen, serum, plasma,
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Not-started
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Clinical records | > 6 months |
| Genomic datasets | > 6 months |
| Imaging data | > 6 months |
| National registries | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Diffuse large B-cell lymphoma (nodal/systemic with skin involvement) (disorder)
ACCEPT
Year Started: 2017
A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patient with Diffuse Large B-cell Lymphoma
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Malignant lymphoma (disorder)
RiVa
Year Started: 2017
A Phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Imaging data | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% |
Malignant lymphoma (disorder)
IELSG 42
Year Started: 2015
An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autologous stem cell transplant, in patients with systemic B-cell lymphoma with central nervous system involvement at diagnosis or relapse (MARIETTA regimen). This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose chemotherapy supported by ASCT.
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Male
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Female
Young adult (18 - 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| There are no material preservation details for this sample set | |||||
Mesothelioma (malignant, clinical disorder) (disorder)
NERO
Year Started: 2022
Multicentre, 2 arm, open-label UK randomised phase II trial in Mesothelioma patients with any histological subtype and any site, who have previously received an approved systemic therapy containing platinum .
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
AURORA
Year Started: 2022
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Psychological data | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Young adult (18 - 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | RT | Not applicable | 75% -99% |
Male
Young adult (18 - 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | RT | Not applicable | 75% -99% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | RT | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |